Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
CMPS:NASDAQ
Compass Pathways PLC
$9.15
+4.57%
(+0.40) 1D
$9.30
+1.64% (+0.15)
Pre-market
Closed: Apr 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPS...
Open
$8.75
High
$9.50
Low
$8.65
Mkt. cap
1.23B
Avg. vol.
3.76M
Volume
18.73K
52-wk high
$10.21
52-wk low
$2.25
EPS
-$3.08
Beta
2.01
Shares outstanding
134.92M
No. of employees
156
News stories
From sources across the web
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
About Compass Pathways PLC
CEO-
Employees156
FoundedJun 13, 2016
Headquarters-
SectorBiotechnology
Websitecompasspathways.com
Next call in 13 days
Thu, May 7, 8:00 AM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-0.32 est.)USD
Revenue / Estimate
-/ (0.00 est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.43M
26.04M
23.40M
42.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.74M
12.61M
13.21M
16.05M
Operating expense
41.17M
38.65M
36.61M
58.86M
Total operating expenses
41.17M
38.65M
36.61M
58.86M
Operating income
-41.17M
-38.65M
-36.61M
-58.86M
Other non operating income
20.26M
-2.72M
-100.94M
-37.79M
EBT including unusual items
-17.51M
-38.27M
-137.95M
-96.61M
EBT excluding unusual items
-17.51M
-38.27M
-137.95M
-96.61M
Income tax expense
354.00K
137.00K
-230.00K
-2.73M
Effective tax rate
-2.02%
-0.36%
0.17%
2.83%
Other operating expenses
-
-
-
-
Net income
-17.86M
-38.40M
-137.72M
-93.88M
Net profit margin
-
-
-
-
Earnings per share
-0.42
-0.41
-0.38
-0.61
Interest and investment income
2.39M
1.90M
1.59M
1.31M
Interest expense
-1.12M
-1.15M
-1.10M
-1.14M
Net interest expenses
1.26M
747.00K
483.00K
173.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.13M
-38.49M
-36.60M
-58.86M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer